Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators
Marco Solmi,Giovanni Croatto,Arnav Gupta,Nicholas Fabiano,Stanley Wong,Michele Fornaro,Lynne Kolton Schneider,S Christy Rohani-Montez,Leanne Fairley,Nathalie Smith,István Bitter,Philip Gorwood,Heidi Taipale,Jari Tiihonen,Samuele Cortese,Elena Dragioti,Ebba Du Rietz,Rene Ernst Nielsen,Joseph Firth,Paolo Fusar-Poli,Catharina Hartman,Richard I G Holt,Anne Høye,Ai Koyanagi,Henrik Larsson,Kelli Lehto,Peter Lindgren,Mirko Manchia,Merete Nordentoft,Karolina Skonieczna-Żydecka,Brendon Stubbs,Davy Vancampfort,Michele De Prisco,Laurent Boyer,Eduard Vieta,Christoph U Correll,ECNP Physical And meNtal Health Thematic Working Group (PAN-Health)
DOI: https://doi.org/10.1016/j.euroneuro.2024.07.009
2024-08-08
Abstract:To further explore the role of different antipsychotic treatments for cardio-cerebrovascular mortality, we performed several subgroup, sensitivity and meta-regression analyses based on a large previous meta-analysis focusing on cohort studies assessing mortality relative risk (RR) for cardio-cerebrovascular disorders in people with schizophrenia, comparing antipsychotic treatment versus no antipsychotic. Quality assessment through the Newcastle-Ottawa Scale (NOS) and publication bias was measured. We meta-analyzed 53 different studies (schizophrenia patients: n = 2,513,359; controls: n = 360,504,484) to highlight the differential effects of antipsychotic treatment regimens on cardio-cerebrovascular-related mortality in incident and prevalent samples of patients with schizophrenia. We found first generation antipsychotics (FGA) to be associated with higher mortality in incident samples of schizophrenia (oral FGA [RR=2.20, 95 %CI=1.29-3.77, k = 1] and any FGA [RR=1.70, 95 %CI=1.20-2.41, k = 1]). Conversely, second generation antipsychotics (SGAs) and clozapine were associated with reduced cardio-cerebrovascular-related mortality, in prevalent samples of schizophrenia. Subgroup analyses with NOS score ≥7 (higher quality) demonstrated a significantly increased cardio-cerebrovascular disorder-related mortality, among those exposed to FGAs vs SGAs. Meta-regression analyses demonstrated a larger association between antipsychotics and decreased risk of mortality with longer follow-up, recent study year, and higher number of adjustment variables. Overall, this subanalysis of a systematic review contributes to the evolving understanding of the complex role of antipsychotic treatment for cardio-cerebrovascular mortality in schizophrenia, paving the way for more targeted interventions and improved patient outcomes.